Date: 0000-00-00
Type of information: Subvention
Company: ImCheck Therapeutics (France)
Investors: Bpifrance (France)
Amount: € 1 million
Funding type: subvention
Planned used:
- The funding will be dedicated to conducting translational studies and launching the production of a novel therapeutic antibody active on both adaptive and innate immune cells and whose target remains confidential at this stage. These studies will be performed in partnership with several renowned international expert academic institutions and will aim at validating the clinical benefit of predictive biomarkers for future treatments as well as study the mechanism of action of the antibody in various hematological cancers (e.g. acute myeloid leukemia, lymphoma) and solid tumors (e.g. colorectal, pancreas, lung, gynecological cancers).
- ImCheck Therapeutics plans to take this first antibody candidate into Phase 1 in 2019 and will apply for further additional non-dilutive funding, notably through the FUI program from Bpifrance.
Others:
- • On September 10, 2017, ImCheck Therapeutics, an emerging biopharmaceutical company developing a new generation of immunomodulatory antibodies against cancer and auto-immune diseases, announced a funding award of €930,000 from Bpifrance to contribute to the advancement of one of its novel immunotherapy program in cancer.
Therapeutic area: Cancer - Oncology
Is general: Yes